Navigation Links
Treating chronic pain, migraine & muscle spasticity through inhibition of neurotransmitter glutamate
Date:6/20/2008

LA JOLLA, CA, June 20, 2008 A Webinar hosted by TorreyPines Therapeutics, Inc. (NASDAQ: TPTX) at 11 a.m. EDT on June 25 will bring together industry experts to discuss the opportunity of treating chronic pain, migraine and muscle spasticity through the inhibition of the neurotransmitter glutamate.

The company's President and Chief Executive Officer, Neil Kurtz, M.D., will moderate a discussion following brief presentations by:

  • Tony Yaksh, Ph.D., Professor and Vice Chairman for Research, Department of Anesthesiology, and Professor of Pharmacology at the University of California, San Diego

    Dr. Yaksh will present information about glutamate receptors in the central nervous system as a target for chronic pain therapy. The focus of his research is the physiology and pharmacology of pain processing. A member of numerous professional societies, Dr. Yaksh has been a consultant to the U.S. Food and Drug Administration and serves on the editorial boards of several journals. He has received many awards, including the FWL Kerr Award from the American Pain Society and the American Society of Anesthesiology Award for Excellence in Research.

  • Jerome Goldstein, M.D., Director of the San Francisco Headache Clinic and a board-certified neurologist who focuses on the diagnosis, treatment, prevention and cure of headache

    Dr. Goldstein will present information about glutamate receptors in the brain as a target for acute and prophylactic migraine therapy. He is a member of the American Headache Society, The International Headache Society and The National Headache Foundation. Dr. Goldstein is a Board Certified Neurologist, a Fellow of the American Academy of Neurology, and has special qualification for the treatment of headache from the National Headache Foundation. He has received many industry awards, published articles in industry journals and served on advisory boards related to the development of a wide range of headache therapies.

  • Alan J. Tuchman, M.D., Clinical Professor of Neurology and Pharmacology at New York Medical College, Principal of a neuroscience-focused consulting firm and a board-certified neurologist

    Dr. Tuchman will present information about glutamate receptors in the spinal cord as a target for muscle spasticity. He has served as Vice Chairman of the Department of Neurology at New York Medical College as well as Vice Dean of Clinical Affairs, which involved the development and management of clinical care and medical education policy for 29 affiliated hospitals. In addition, he was President of the Epilepsy Society of Southern New York. Dr. Tuchman is a frequent speaker about neuroscience topics at academic meetings.

"There's a growing body of scientific and clinical evidence that supports the further development of drugs that block the glutamate cascade," said Dr. Kurtz. "As the American Headache Society prepares to kick off its 50th Annual Scientific Meeting, we want to provide patients as well as the medical community with industry experts' perspectives as to what is clearly a promising approach for the treatment of migraine and other conditions."

TorreyPines Therapeutics' lead compound, tezampanel is the first AMPA/kainate-type glutamate receptor antagonist to be studied in clinical trials for chronic pain. Glutamate receptors mediate the functioning of glutamate, an important excitatory neurotransmitter. While normal glutamate production is essential, excess glutamate production, either through injury or disease, can have a range of pathological effects. By acting at both the AMPA and kainate receptor site to competitively block the binding of glutamate, tezampanel and its oral prodrug, NGX426, have the potential to treat a number of diseases and disorders. These include migraine and other forms of chronic pain such as neuropathic pain as well as muscle spasticity and rigidity secondary to spinal cord trauma, stroke and multiple sclerosis.


'/>"/>

Contact: Wendy Lau
wendy.lau@russopartnersllc.com
212-845-4272
Russo Partners, LLC
Source:Eurekalert

Related biology news :

1. Environmental epigenetics has potential for preventing and treating disease
2. International scientists tackle obstacles to treating brain disorders
3. Sirtris unveils promising, novel SIRT1 activators for treating diseases of aging
4. Massive microRNA scan uncovers leads to treating muscle degeneration
5. Gregory Hannon wins 2007 Paul Marks Prize for contributions to understanding and treating cancer
6. Gamma globulin effective in treating eye infections caused by adenoviruses
7. Domestic violence associated with chronic malnutrition in women and children in India
8. Diet support helps chronic kidney patients
9. SinuNase Phase 3 show almost 100 percent of chronic sinusitis cases are from fungal-induced inflamma
10. Continuous oral contraceptives better at easing pain, bleeding
11. How does the opioid system control pain, reward and addictive behavior?
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/9/2016)... UAE, May 9, 2016 Elevay ... comes to expanding freedom for high net worth professionals ... in today,s globally connected world, there is still no ... could ever duplicate sealing your deal with a firm ... passports by taking advantage of citizenship via investment programs ...
(Date:4/26/2016)... April 27, 2016 Research ... Multi-modal Biometrics Market 2016-2020"  report to their offering.  ... The analysts forecast the global multimodal ... 15.49% during the period 2016-2020.  Multimodal ... sectors such as the healthcare, BFSI, transportation, automotive, ...
(Date:4/13/2016)... -- IMPOWER physicians supporting Medicaid patients in Central ... in telehealth thanks to a new partnership with higi. ... patients can routinely track key health measurements, such as ... when they opt in, share them with IMPOWER clinicians ... retail location at no cost. By leveraging this data, ...
Breaking Biology News(10 mins):
(Date:6/27/2016)... ... June 27, 2016 , ... Rolf K. Hoffmann, former senior ... the University of North Carolina Kenan-Flagler Business School effective June 27. ... Kenan-Flagler, with a focus on the school’s international efforts, leading classes and participating ...
(Date:6/24/2016)... -- Regular discussions on a range of subjects including policies, debt ... said Poloz. Speaking at a lecture to the ... pointed to the country,s inflation target, which is set by ... "In certain areas there needs to ... goals, why not sit down and address strategy together?" ...
(Date:6/24/2016)... Raleigh, NC (PRWEB) , ... June 24, 2016 , ... ... find the most commonly-identified miRNAs in people with peritoneal or pleural mesothelioma. Their findings ... here to read it now. , Diagnostic biomarkers are signposts in the blood, ...
(Date:6/23/2016)... June 23, 2016   Boston Biomedical , ... compounds designed to target cancer stemness pathways, announced ... granted Orphan Drug Designation from the U.S. Food ... gastric cancer, including gastroesophageal junction (GEJ) cancer. Napabucasin ... to inhibit cancer stemness pathways by targeting STAT3, ...
Breaking Biology Technology: